Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. [electronic resource]
Producer: 20120112Description: 16507-16 p. digitalISSN:- 1529-2401
- Adult
- Alzheimer Disease -- cerebrospinal fluid
- Amyloid Precursor Protein Secretases -- analysis
- Amyloid beta-Peptides -- cerebrospinal fluid
- Amyloid beta-Protein Precursor -- cerebrospinal fluid
- Analysis of Variance
- Animals
- Aspartic Acid Endopeptidases -- analysis
- Cells, Cultured
- Cerebral Cortex -- cytology
- Crystallography -- methods
- Disease Models, Animal
- Dogs
- Dose-Response Relationship, Drug
- Embryo, Mammalian
- Enzyme Inhibitors -- blood
- Enzyme-Linked Immunosorbent Assay -- methods
- Female
- Humans
- Male
- Mice
- Mice, Transgenic
- Middle Aged
- Models, Chemical
- Mutation -- genetics
- Neurons -- drug effects
- Peptide Fragments -- cerebrospinal fluid
- Pyrimidines -- pharmacology
- Rats
- Rats, Sprague-Dawley
- Thiazines -- pharmacology
- Time Factors
- Young Adult
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.